

# MLN Matters®

Information for Medicare Fee-For-Service Health Care Professionals

MLN Matters Number: MM3552

Related Change Request (CR) #: 3552

Related CR Release Date: November 5, 2004

Effective Date: April 1, 2004

Related CR Transmittal #: R361CP

Implementation Date: December 6, 2004

## MMA Drug Pricing Update—Payment Limit for J0207 (Amifostine)

**Note:** This article was updated on May 12, 2013, to reflect current Web addresses. All other information remains unchanged.

### Provider Types Affected

Physicians and providers billing Medicare carriers for Amifostine

### Provider Action Needed

This article informs affected providers that Medicare will implement the Medicare Modernization Act of 2003 (MMA) payment limit for Amifostine (HCPCS drug code J0207) with the new rate listed in this article for dates of service starting April 1, 2004, through December 31, 2004.

Please note that this payment limit for Amifostine (J0207) supercedes the payment limit published in Change Request (CR) 3161, Transmittal 119, dated March 15, 2004, and any other publication published prior to this document.

### Background

The MMA (Section 303(b)(2)) specifies that the Centers for Medicare & Medicaid Services (CMS) may adjust the percentage used in the calculation for pricing Medicare Part B drugs effective January 1, 2004 (based on data and information submitted by the manufacturer after October 15, 2003 and before January 1, 2004).

Therefore, based on information received by CMS, the payment limit for Amifostine (J0207) has been revised.

From April 1, 2004 through December 31, 2004, the Medicare payment limit for the Healthcare Common Procedure Coding System (HCPCS) drug code J0207 applies when it is not paid on a cost or prospective payment basis. The old and revised payment limits are as follows:

#### Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents.

Status	HCPCS	Short Description	Average Wholesale Price (AWP) %	2004 Payment Limit for Drugs (other than End Stage Renal Disease (ESRD) drugs separately billed by independent ESRD Facilities and drugs infused through Durable Medical Equipment (DME))
OLD	J0207	Amifostine	85	\$405.29
NEW	J0207	Amifostine	89	\$422.21

Note that the absence or presence of a HCPCS code and its associated payment limit does not indicate Medicare coverage of the drug.

## Additional Information

To view the official instruction issued to your carrier regarding this change, go to <http://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R361CP.pdf> on the CMS website.

If you have any questions, please contact your carrier at their toll-free number, which may be found at <http://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/provider-compliance-interactive-map/index.html> on the CMS website.

### Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents.